Edwards Lifesciences Corporation $EW Shares Sold by Capital Insight Partners LLC

Key Points

• Capital Insight Partners LLC reduced its stake in Edwards Lifesciences by 14.1% during Q2, now holding 49,307 shares valued at approximately $3.86 million.
• Several institutional investors have recently invested in Edwards Lifesciences, with a reported 79.46% of the company's stock owned by hedge funds and institutional investors.
• Edwards Lifesciences' Q2 earnings report showed an EPS of $0.67, surpassing analysts' expectations and reflecting a 11.9% revenue increase year-over-year.

Capital Insight Partners LLC lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 14.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,307 shares of the medical research company's stock after selling 8,108 shares during the quarter. Capital Insight Partners LLC's holdings in Edwards Lifesciences were worth $3,856,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. SouthState Corp bought a new stake in Edwards Lifesciences in the first quarter valued at about $27,000. Global X Japan Co. Ltd. raised its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares in the last quarter. Tradewinds Capital Management LLC lifted its holdings in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the last quarter. Finally, Rossby Financial LCC bought a new stake in Edwards Lifesciences during the first quarter valued at $29,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $76.34 on Monday. The stock has a market cap of $44.82 billion, a P/E ratio of 10.98, a P/E/G ratio of 3.67 and a beta of 1.07. The firm's 50-day simple moving average is $78.50 and its 200 day simple moving average is $75.78. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the firm posted $0.70 EPS. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Mizuho boosted their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Finally, BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a research report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.